513 related articles for article (PubMed ID: 23280794)
1. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.
Yousry TA; Pelletier D; Cadavid D; Gass A; Richert ND; Radue EW; Filippi M
Ann Neurol; 2012 Nov; 72(5):779-87. PubMed ID: 23280794
[TBL] [Abstract][Full Text] [Related]
2. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
Wattjes MP; Richert ND; Killestein J; de Vos M; Sanchez E; Snaebjornsson P; Cadavid D; Barkhof F
Mult Scler; 2013 Dec; 19(14):1826-40. PubMed ID: 24192217
[TBL] [Abstract][Full Text] [Related]
3. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
4. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.
Kleinschmidt-DeMasters BK; Miravalle A; Schowinsky J; Corboy J; Vollmer T
J Neuropathol Exp Neurol; 2012 Jul; 71(7):604-17. PubMed ID: 22710964
[TBL] [Abstract][Full Text] [Related]
5. A rational approach to PML for the clinician.
Calabrese L
Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S38-41. PubMed ID: 22123934
[TBL] [Abstract][Full Text] [Related]
6. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
Eisele P; Szabo K; Hornberger E; Griebe M; Hennerici MG; Kieseier BC; Gass A
J Neuroimaging; 2014; 24(4):425-8. PubMed ID: 23323645
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI.
Wattjes MP; Barkhof F
Curr Opin Neurol; 2014 Jun; 27(3):260-70. PubMed ID: 24739400
[TBL] [Abstract][Full Text] [Related]
8. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
Boster AL; Nicholas JA; Topalli I; Kisanuki YY; Pei W; Morgan-Followell B; Kirsch CF; Racke MK; Pitt D
JAMA Neurol; 2013 Mar; 70(3):398-402. PubMed ID: 23338729
[TBL] [Abstract][Full Text] [Related]
9. Review of progressive multifocal leukoencephalopathy and natalizumab.
Aksamit AJ
Neurologist; 2006 Nov; 12(6):293-8. PubMed ID: 17122725
[TBL] [Abstract][Full Text] [Related]
10. MRI pattern in asymptomatic natalizumab-associated PML.
Wattjes MP; Vennegoor A; Steenwijk MD; de Vos M; Killestein J; van Oosten BW; Mostert J; Siepman DA; Moll W; van Golde AE; Frequin ST; Richert ND; Barkhof F
J Neurol Neurosurg Psychiatry; 2015 Jul; 86(7):793-8. PubMed ID: 25205744
[TBL] [Abstract][Full Text] [Related]
11. Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study.
Boster A; Hreha S; Berger JR; Bao F; Penmesta R; Tselis A; Endress C; Zak I; Perumal J; Caon C; Vazquez J; Tyler KL; Racke MK; Millis S; Khan O
Arch Neurol; 2009 May; 66(5):593-9. PubMed ID: 19433659
[TBL] [Abstract][Full Text] [Related]
12. MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS.
Wattjes MP; Wijburg MT; Vennegoor A; Witte BI; de Vos M; Richert ND; Uitdehaag BM; Barkhof F; Killestein J;
J Neurol Neurosurg Psychiatry; 2016 Aug; 87(8):879-84. PubMed ID: 26369555
[TBL] [Abstract][Full Text] [Related]
13. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.
Metz I; Radue EW; Oterino A; Kümpfel T; Wiendl H; Schippling S; Kuhle J; Sahraian MA; Gray F; Jakl V; Häusler D; Brück W
Acta Neuropathol; 2012 Feb; 123(2):235-45. PubMed ID: 22057786
[TBL] [Abstract][Full Text] [Related]
14. Natalizumab (tysabri)-associated progressive multifocal leukoencephalopathy: insights from perfusion magnetic resonance imaging.
Elster MJ
J Comput Assist Tomogr; 2013; 37(5):694-7. PubMed ID: 24045242
[TBL] [Abstract][Full Text] [Related]
15. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.
Wenning W; Haghikia A; Laubenberger J; Clifford DB; Behrens PF; Chan A; Gold R
N Engl J Med; 2009 Sep; 361(11):1075-80. PubMed ID: 19741228
[TBL] [Abstract][Full Text] [Related]
16. Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
Fine AJ; Sorbello A; Kortepeter C; Scarazzini L
Ann Neurol; 2014 Jan; 75(1):108-15. PubMed ID: 24242357
[TBL] [Abstract][Full Text] [Related]
17. Magnetic resonance imaging changes following natalizumab discontinuation in multiple sclerosis patients with progressive multifocal leukoencephalopathy.
Hodel J; Bapst B; Outteryck O; Verclytte S; Deramecourt V; Benadjaoud MA; Pruvo JP; Vermersch P; Leclerc X
Mult Scler; 2018 Dec; 24(14):1902-1908. PubMed ID: 29343163
[TBL] [Abstract][Full Text] [Related]
18. The earlier, the smaller, the better for natalizumab-associated PML: in MRI vigilance veritas?
Phan-Ba R; Belachew S; Outteryck O; Moonen G; Sindic C; Vokaer M; Vermersch P
Neurology; 2012 Sep; 79(10):1067-9. PubMed ID: 22914844
[No Abstract] [Full Text] [Related]
19. MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance.
Wijburg MT; Witte BI; Vennegoor A; Roosendaal SD; Sanchez E; Liu Y; Martins Jarnalo CO; Uitdehaag BM; Barkhof F; Killestein J; Wattjes MP
J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1138-45. PubMed ID: 27530808
[TBL] [Abstract][Full Text] [Related]
20. Atypical MRI features at early onset natalizumab-associated progressive multifocal leukoencephalopathy: a case report.
Piola M; Di Palma F; Mascoli N; Binda S; Arnaboldi M; Rezzonico M
J Neurol Sci; 2014 May; 340(1-2):213-4. PubMed ID: 24642511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]